23 Jul, 2026
According to Straits Research, the global pharmaceutical contract development and manufacturing organization (CDMO) market size was valued at $214.56 billion in 2025 and is projected to grow from $229.15 billion in 2026 to $387.88 billion by 2034, registering a CAGR of 6.8% during the forecast period 2026–2034.
A pharmaceutical contract development and manufacturing organization (CDMO) is a specialized service provider that offers comprehensive support to pharmaceutical companies, covering drug development, manufacturing, and packaging. CDMOs facilitate the entire drug development process, from preclinical formulation to large-scale production, while ensuring regulatory compliance. By outsourcing these functions, pharmaceutical companies can enhance efficiency, reduce costs, and accelerate time-to-market for their products.
Expansion of clinical trials drives demand for CDMO expertise
The increasing number of clinical trials is significantly driving demand for pharmaceutical CDMO services, primarily due to the complexities involved in drug development. Many pharmaceutical companies lack the necessary resources and expertise for manufacturing and regulatory compliance, making CDMOs vital partners.
Moreover, they provide specialized services, including formulation development, clinical trial material production, and quality assurance, helping drug developers accelerate timelines, reduce costs, and manage risks.
Leveraging process automation in CDMO operations
The adoption of process automation presents a transformative opportunity for pharmaceutical CDMOs, enhancing production efficiency and reliability. By utilizing advanced software, sensors, and PLCs, CDMOs can optimize manufacturing workflows, minimize human error, and boost productivity.
This approach not only ensures high product quality but also lowers operational costs and accelerates timelines, enhancing the competitiveness of CDMOs in the supply chain.
The North American pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is the largest globally, significantly influenced by the presence of major pharmaceutical and biotechnology companies. This concentration leads to considerable investments in biopharmaceutical research and development, driven by a rising demand for innovative therapies, particularly in cell and gene therapies. However, the U.S. market faces challenges, including drug shortages caused by production delays, discontinuations, and quality control issues, highlighting the need for more robust manufacturing solutions.
In contrast, the Asia Pacific region is witnessing rapid growth in the CDMO sector, fueled by lower operational costs and an increasing prevalence of chronic diseases such as diabetes and heart conditions. This rising demand for new therapies prompts pharmaceutical companies to outsource research and manufacturing activities to CDMOs. Moreover, the trend of privatizing clinical trials is enhancing research outsourcing in developing nations like China and India, further propelling the CDMO market's expansion in this region.
sales@straitsresearch.com